Faster Time to Market: Approaches to Biometrics for Emerging Biopharma Companies
Emerging biopharma companies (EBPs) are now leading clinical trial activity, but biometrics is becoming increasingly complex. To navigate these challenges, many are moving away from full-service CROs and choosing specialized biometrics providers to ensure data integrity, flexibility, and operational efficiency.
This Frost & Sullivan report, sponsored by Bioforum explores:
🔹 The evolving role of biometrics in modern clinical trials
🔹 Key challenges faced by EBPs, including decentralized trials and adaptive trial designs
🔹 Why companies are opting for biometrics-focused CROs instead of full-service providers
🔹 Best practices for ensuring regulatory compliance and optimizing data workflows
Key Takeaways:
✅ Data Complexity is Rising – EBPs face mounting challenges in structuring and managing clinical data efficiently.
✅ Regulatory Expectations are Growing – Agencies demand more standardized, high-quality data submissions.
✅ Specialized Biometrics CROs are Gaining Favor – Companies prefer focused expertise over large, one-size-fits-all providers.
✅ Technology & Integration Matter – Seamless data flow between platforms is critical for trial success.
Download the full report to dive deeper into these industry-changing insights.